LENZ Therapeutics, Inc.
LENZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 150% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -132.6% | -336.8% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -133.6% | -298.2% | – | – |
| EPS Diluted | -0.59 | -0.53 | -0.53 | -0.46 |
| % Growth | -11.3% | 0% | -15.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |